MedCity News
Truepill becomes a ‘triple threat’ with diagnostics
Truepill, the company operating behind-the-scenes to help digital health companies with pharmacy fulfillment and telehealth visits, has added a third feature: at home testing. CEO Umar Afridi hopes the trio of services will create a seamless experience for most people’s basic health needs.
Shares0
Truepill, a company operating behind-the-scenes of several well-known digital health brands and health plans, added another tool to its repertoire: diagnostics. The San Francisco-based company is now ‘triple threat’ of sorts, offering white-labeled pharmacy fulfillment, telehealth and lab testing all in one place.
“There’s no other company that offers all three under one roof where it’s a seamless experience,” CEO Umar Afridi said in a phone interview.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
24 maggio 2021 07:05
Fonte: Adnkronos
#salute-e-benessere
SEOUL, South Korea, May 21, 2021 /PRNewswire/ On the 20th, the Medical robot specialist company CUREXO Corp. (060280) announced their independently developed spinal surgery robot CUVIS-spine has acquired FDA (US) licensing.
This FDA (US) license, followed by Korea (2019) and Europe CE (2020) certificate is the 3rd license that they have acquired and now their product can be supplied to all countries.
Currently, 2 CUVIS-spine s are being used in Severance Hospital (Korea) and 1 has been exported to an Australian medical facility company. CUREXO also plans to expand their focus on global markets including the US and Europe.
Spinal surgery robot CUVIS-spine is a next-gen spinal surgery robot that guides the insertion of a pedicle screw according to the surgery plan. It uses a high precision robot arm, wireless one-step, navigation based on a real-time GPS sensor to provide precise, safe and faster surgery compared to
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
MedCity News
Docbot CEO highlights how AI can be applied to gastrointestinal image analysis
Docbot CEO Andrew Ritter talked about how the predictive analytics business seeks to shake up how clinicians diagnose gastrointestinal disease by changing the way medical images are analyzed.
Shares0
In an interview, Docbot CEO Andrew Ritter talked about how the predictive analytics business seeks to shake up how clinicians diagnose gastrointestinal disease by changing the way medical images are analyzed.
Why did you start this company?
The original co-founder, Andrew Ninh started the company because he experienced a collapsed lung which caused him to miss his high school graduation. During this time, he saw that healthcare desperately needed IT systems that are safer for patients, physicians and nurses. He later met Dr. William Karnes, a leading gastroenterologist at UC Irvine, who explained the current standard of care for colonoscopies. Together, they started Docbot, a predictive ar